Webbed HIV Immunogens Stabilize Trimers via M9 Toxin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV Env immunogens fail to elicit high-titer broadly neutralizing antibodies, particularly against primary HIV isolates, due to inadequate immunogenicity of conserved neutralizing epitopes and instability of trimeric structures, which limits their effectiveness in inducing long-lived protection.
Innovation Solution
Development of 'webbed' HIV Env immunogens that stabilize native envelope structures through non-covalent bonding with derivatives of scorpion M9 toxin, promoting multivalent display of native Env and CD4i epitopes, enhancing immunogenicity and neutralizing activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HIV Env immunogens are used, then the structure is simpler to produce, but the trimeric structure is unstable and fails to elicit high-titer broadly neutralizing antibodies
Solution Approach 1:
The patent introduces M9 scorpion toxin as an intermediary stabilizing molecule that binds to the Env trimer through non-covalent interactions. M9 acts as a molecular bridge that reinforces the trimeric structure without covalently modifying the native Env proteins, thereby stabilizing the immunogen while preserving its native antigenic properties for eliciting neutralizing antibodies.
Solution Approach 2:
The immunogen formulation combines multiple components: native Env trimers, M9 scorpion toxin derivatives, and adjuvants into a composite structure. This composite approach allows the M9 toxin to provide structural stability while the Env proteins maintain their immunogenicity, creating a synergistic formulation that overcomes the limitations of either component alone.
2Reliability
If conventional Env immunogens are used, then the formulation is simpler, but the immunogenicity of conserved neutralizing epitopes is inadequate
Solution Approach 1:
M9 scorpion toxin serves as an intermediary that selectively binds to and stabilizes conserved neutralizing epitopes on the Env trimer. This intermediary interaction enhances the exposure and immunogenicity of these conserved epitopes without requiring complex genetic modification of the Env proteins themselves, thereby improving antibody elicitation while managing formulation complexity.
Solution Approach 2:
The patent utilizes M9 toxin to induce conformational changes in the Env trimer that optimize the exposure and accessibility of conserved neutralizing epitopes. By changing the structural parameters of the immunogen through non-covalent binding, the immunogenicity of key epitopes is enhanced, allowing for better antibody responses without overly complicating the production process.
3Stability of the object's composition
If Env trimers are stabilized through non-covalent bonding with M9 toxin, then the trimeric structure is stabilized and epitopes are exposed, but the formulation becomes more complex
Solution Approach 1:
M9 toxin acts as a stabilizing intermediary that forms non-covalent bonds with the Env trimer, providing structural reinforcement without requiring complex covalent chemistry or genetic engineering. This mediator approach stabilizes the trimeric composition through relatively simple molecular interactions that can be achieved through straightforward formulation processes.
Solution Approach 2:
The M9 toxin naturally possesses binding affinity for the Env trimer through its inherent molecular structure. This self-service property allows the toxin to spontaneously stabilize the immunogen formulation without requiring complex external stabilization mechanisms, reducing the overall complexity of the formulation process while maintaining trimer stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The webbed immunogens effectively stabilize trimeric structures and expose conserved epitopes, potentially inducing broad neutralization capabilities against a wide array of HIV-1 isolates, offering a more effective vaccine approach by enhancing antibody responses and stability.
Implementation Method 1
stabilize the trimeric structure of Env and display multivalent native Env and CD4i epitopes... through non-covalent bonding with derivatives of scorpion M9 toxin
Data Source
AI summary
HIV envelope immunogens that display multivalent epitopes are provided. The immunogens are aggregated, “webbed” HIV envelope immunogens in which native envelope structures are stabilized due to interactions with multimeric derivatives of M9 scorpion toxin.